Creative Medical Technology Holdings, Inc. (CELZ) stock
CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.53−0.09 (-14.35%)
Close on Nov 13, 2026Market cap $3.48MP/E –Yield –
Creative Medical Technology cash
Cash and short-term investments held at the end of each period.
Creative Medical Technology's cash was $6.85M at Sep 30, 2026. For fiscal 2025 it was $7.21M, up 21.3% from the year before. Over ten years it grew 206.0% a year on average. The highest annual figure on record is $10.72M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.21M | +21.3% |
| FY2024 | Dec 31, 2024 | $5.94M | +71.3% |
| FY2023 | Dec 31, 2023 | $3.47M | -58.3% |
| FY2022 | Dec 31, 2022 | $8.32M | -22.4% |
| FY2021 | Dec 31, 2021 | $10.72M | +10841.4% |
| FY2020 | Dec 31, 2020 | $98.01K | +10.6% |
| FY2019 | Dec 31, 2019 | $88.65K | -70.8% |
| FY2018 | Dec 31, 2018 | $304.06K | +2119.9% |
| FY2017 | Dec 31, 2017 | $13.70K | -93.8% |
| FY2016 | Dec 31, 2016 | $221.87K | +221768.0% |
| FY2015 | Dec 31, 2015 | $100 | -89.5% |
| FY2014 | Dec 31, 2014 | $954 | +155.1% |
| FY2013 | Dec 31, 2013 | $374 | -52.1% |
| FY2012 | Dec 31, 2012 | $781 | -29.3% |
| FY2011 | Dec 31, 2011 | $1.11K | +166.9% |
| FY2010 | Dec 31, 2010 | $414 | -28.0% |
| FY2009 | Dec 31, 2009 | $575 | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $6.85M | +27.4% |
| Q2 FY2026 | Jun 30, 2026 | $8.71M | +33.0% |
| Q1 FY2026 | Mar 31, 2026 | $5.72M | -25.7% |
| Q4 FY2025 | Dec 31, 2025 | $7.21M | +21.3% |
| Q3 FY2025 | Sep 30, 2025 | $5.38M | -14.1% |
| Q2 FY2025 | Jun 30, 2025 | $6.55M | -12.3% |
| Q1 FY2025 | Mar 31, 2025 | $7.70M | -14.5% |
| Q4 FY2024 | Dec 31, 2024 | $5.94M | +71.3% |
| Q3 FY2024 | Sep 30, 2024 | $6.26M | +38.9% |
| Q2 FY2024 | Jun 30, 2024 | $7.47M | +87.3% |
| Q1 FY2024 | Mar 31, 2024 | $9.01M | -5.3% |
| Q4 FY2023 | Dec 31, 2023 | $3.47M | -58.3% |
| Q3 FY2023 | Sep 30, 2023 | $4.51M | -73.4% |
| Q2 FY2023 | Jun 30, 2023 | $3.99M | -82.6% |
| Q1 FY2023 | Mar 31, 2023 | $9.52M | +4.0% |
| Q4 FY2022 | Dec 31, 2022 | $8.32M | -22.4% |
| Q3 FY2022 | Sep 30, 2022 | $16.97M | +613.6% |
| Q2 FY2022 | Jun 30, 2022 | $22.86M | +14317.0% |
| Q1 FY2022 | Mar 31, 2022 | $9.15M | +3224.6% |
| Q4 FY2021 | Dec 31, 2021 | $10.72M | +10841.4% |
| Q3 FY2021 | Sep 30, 2021 | $2.38M | +6043.6% |
| Q2 FY2021 | Jun 30, 2021 | $158.59K | +328.4% |
| Q1 FY2021 | Mar 31, 2021 | $275.13K | +617.9% |
| Q4 FY2020 | Dec 31, 2020 | $98.01K | +10.6% |
| Q3 FY2020 | Sep 30, 2020 | $38.71K | -75.5% |
| Q2 FY2020 | Jun 30, 2020 | $37.02K | -81.9% |
| Q1 FY2020 | Mar 31, 2020 | $38.33K | -90.9% |
| Q4 FY2019 | Dec 31, 2019 | $88.65K | -70.8% |
| Q3 FY2019 | Sep 30, 2019 | $158.24K | -8.4% |
| Q2 FY2019 | Jun 30, 2019 | $204.11K | +103.1% |
| Q1 FY2019 | Mar 31, 2019 | $419.48K | +310.0% |
| Q4 FY2018 | Dec 31, 2018 | $304.06K | +2119.9% |
| Q3 FY2018 | Sep 30, 2018 | $172.83K | +714.6% |
| Q2 FY2018 | Jun 30, 2018 | $100.50K | -3.7% |
| Q1 FY2018 | Mar 31, 2018 | $102.31K | +4.3% |
| Q4 FY2017 | Dec 31, 2017 | $13.70K | -93.8% |
| Q3 FY2017 | Sep 30, 2017 | $21.22K | – |
| Q2 FY2017 | Jun 30, 2017 | $104.40K | – |
| Q1 FY2017 | Mar 31, 2017 | $98.12K | – |
| Q4 FY2016 | Dec 31, 2016 | $221.87K | – |
See a number that looks wrong?